Research Analysts Offer Predictions for STOK Q3 Earnings

Key Points

• HC Wainwright adjusted its earnings per share (EPS) estimate for Stoke Therapeutics' Q3 2025 from (0.69) to (0.60), maintaining a "Buy" rating with a target price of $35.00.
• Stoke Therapeutics reported a Q3 earnings result of (0.40) EPS, surpassing the consensus estimate of (0.57), although revenue of $13.82 million fell short of the expected $31.51 million.
• Multiple brokerages have issued buy ratings on the stock, with consensus implying a target price of $25.17 based on an average of analysts' ratings.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.60) for the quarter, up from their previous estimate of ($0.69). HC Wainwright currently has a "Buy" rating and a $35.00 target price on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics' Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at ($3.07) EPS, FY2027 earnings at ($2.13) EPS, FY2028 earnings at ($1.09) EPS and FY2029 earnings at $0.46 EPS.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. The company had revenue of $13.82 million for the quarter, compared to analysts' expectations of $31.51 million.

A number of other brokerages have also recently issued reports on STOK. Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Wedbush lifted their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research report on Wednesday. Jefferies Financial Group began coverage on Stoke Therapeutics in a research report on Friday, July 18th. They set a "buy" rating and a $30.00 price objective for the company. Chardan Capital reissued a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of "Buy" and a consensus target price of $25.17.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $17.17 on Friday. The stock has a market cap of $940.92 million, a PE ratio of 20.20 and a beta of 1.15. The business's fifty day moving average is $12.41 and its 200-day moving average is $10.11. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $17.61.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 4,504 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $12.82, for a total value of $57,741.28. Following the sale, the insider directly owned 16,775 shares in the company, valued at approximately $215,055.50. This represents a 21.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders sold 12,720 shares of company stock valued at $140,095. 9.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE grew its stake in shares of Stoke Therapeutics by 2.9% in the 2nd quarter. Bank of America Corp DE now owns 548,090 shares of the company's stock valued at $6,221,000 after purchasing an additional 15,206 shares during the period. MPM Bioimpact LLC grew its position in Stoke Therapeutics by 13.8% during the 2nd quarter. MPM Bioimpact LLC now owns 789,698 shares of the company's stock worth $8,963,000 after acquiring an additional 95,710 shares during the last quarter. Jane Street Group LLC grew its position in Stoke Therapeutics by 28.8% during the 2nd quarter. Jane Street Group LLC now owns 34,743 shares of the company's stock worth $394,000 after acquiring an additional 7,765 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Stoke Therapeutics by 121.0% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,411 shares of the company's stock worth $607,000 after acquiring an additional 29,244 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Stoke Therapeutics by 14.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,099 shares of the company's stock worth $171,000 after acquiring an additional 1,862 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.